HYDROMORPHONE 8 MG — DIN 02192144
HYDROMORPHONE HYDROCHLORIDE : 8 MG · SORRES PHARMA INC · TABLET · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is HYDROMORPHONE?
HYDROMORPHONE 8 MG contains HYDROMORPHONE HYDROCHLORIDE : 8 MG. It is listed in the Health Canada Drug Product Database under DIN 02192144, held by SORRES PHARMA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 20-Jun-2014. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is HYDROMORPHONE used for?
HYDROmorphone (HYDROmorphone hydrochloride) is indicated for relief of moderate to severe pain.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Hydromorphone cost around the world?
Hydromorphone is listed on 2 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; United States publishes a acquisition. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Australia | ex-manufacturer | 10 | 37 | AUD███.██ |
| United States | acquisition | 10 | 26 | USD███.██ |
63 pack listings across 20 brand entries and 2 price bases, refreshed 08 Sep 2026. Ranges span every Hydromorphone pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Hydromorphone in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
15 holders have a Canadian DIN containing Hydromorphone, across 85 DINs, of which 34 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| PURDUE PHARMA | 25 | 12 | DILAUDID, DILAUDID HP, DILAUDID-HP-PLUS, DILAUDID-XP, HYDROMORPH CONTIN, +12 more | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 7 | 5 | HYDROMORPHONE HP 10, HYDROMORPHONE HP 20, HYDROMORPHONE HP 50, HYDROMORPHONE HP FORTE INJECTION, HYDROMORPHONE HYDROCHLORIDE INJECTION USP, +1 more | Sourceable in Canada |
| PHARMASCIENCE INC | 6 | 5 | PMS HYDROMORPHONE SIROP 1MG/ML, PMS HYDROMORPHONE SUPPOSITOIRE 3MG, PMS-HYDROMORPHONE TAB 1MG, PMS-HYDROMORPHONE TAB 2MG, PMS-HYDROMORPHONE TAB 4MG, +1 more | Sourceable in Canada |
| APOTEX INC | 12 | 4 | APO-HYDROMORPHONE, APO-HYDROMORPHONE CR | Sourceable in Canada |
| STERIMAX INC | 5 | 4 | HYDROMORPHONE HYDROCHLORIDE INJECTION, HYDROMORPHONE HYDROCHLORIDE INJECTION HP 10, HYDROMORPHONE HYDROCHLORIDE INJECTION HP 50, HYDROMORPHONE HYDROCHLORIDE INJECTION HP FORTE | Sourceable in Canada |
| FRESENIUS KABI CANADA LTD | 2 | 2 | HYDROMORPHONE HYDROCHLORIDE INJECTION, USP | Sourceable in Canada |
| STERINOVA INC. | 2 | 2 | HYDROMORPHONE HYDROCHLORIDE INJECTION USP | Sourceable in Canada |
| BARD PHARMACEUTICALS (1990) INC | 8 | 0 | BAR-HYDROMORPHONE CR | No marketed DIN |
| JANSSEN INC | 4 | 0 | JURNISTA | No marketed DIN |
| SORRES PHARMA INC | 4 | 0 | HYDROMORPHONE | No marketed DIN |
| TEVA CANADA LIMITED | 4 | 0 | TEVA-HYDROMORPHONE | No marketed DIN |
| PHARMEL INC | 2 | 0 | PHL-HYDROMORPHONE, PHL-HYDROMORPHONE -SYR 1MG/ML | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 8 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | Bottles of 100 and Control Packs of 4 x 25. |
| Storage | The tablets should be stored at 15-30 °C. Protect from light. |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Hydromorphone |
|---|---|
| ATC code | N02AA03 |
| AHFS class | 28:08.08 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02192144 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2192144 |
| Brand name | HYDROMORPHONE |
| Generic / active ingredient | HYDROMORPHONE HYDROCHLORIDE : 8 MG |
| Market authorization holder | SORRES PHARMA INC |
| Health Canada schedule | NARCOTICS (CDSA I) |
| ATC code | N02AA03 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N02AA |
| Current status | CANCELLED POST MARKET |
| Status date | 20-Jun-2014 |
| Original market date | 2004-04-06 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Orally, for adults, 2 to 4 mg every 4 to 6 hours as required. Dose should be adjusted so that 3-4 hours of pain relief may be achieved.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Known hypersensitivity to the drug; respiratory depression in the absence of resuscitative equipment; status asthmaticus.
Warnings and precautions
Potential for drug dependence and abuse. Risk of severe respiratory depression, especially in elderly/debilitated. May increase intracranial pressure. May cause severe hypotension.
Is Hydromorphone in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Active — reported by STERIMAX INC, last seen 09 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
34 of 85 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-HYDROMORPHONE | 1 MG | TABLET | APOTEX INC | MARKETED | 02364115 |
| APO-HYDROMORPHONE | 2 MG | TABLET | APOTEX INC | MARKETED | 02364123 |
| APO-HYDROMORPHONE | 8 MG | TABLET | APOTEX INC | MARKETED | 02364158 |
| APO-HYDROMORPHONE | 4 MG | TABLET | APOTEX INC | MARKETED | 02364131 |
| DILAUDID | 1 MG | TABLET | PURDUE PHARMA | MARKETED | 00705438 |
| DILAUDID | 4 MG | TABLET | PURDUE PHARMA | MARKETED | 00125121 |
| DILAUDID | 2 MG | TABLET | PURDUE PHARMA | MARKETED | 00125083 |
| DILAUDID | 8 MG | TABLET | PURDUE PHARMA | MARKETED | 00786543 |
| HYDROMORPH CONTIN | 9 MG | CAPSULE (SUSTAINED-RELEASE) | PURDUE PHARMA | MARKETED | 02359510 |
| HYDROMORPH CONTIN | 4.5 MG | CAPSULE (SUSTAINED-RELEASE) | PURDUE PHARMA | MARKETED | 02359502 |
2 · Same class — other molecules in ATC N02AA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Morphine | BAR-MORPHINE SR · DOLORAL SIROP · KADIAN · M-EDIAT · +86 more | 172 | 56 | Yes |
| Hydromorphone | APO-HYDROMORPHONE · APO-HYDROMORPHONE CR · BAR-HYDROMORPHONE CR · DILAUDID · +40 more | 85 | 34 | Yes |
| Oxycodone | ACT OXYCODONE CR · APO-OXYCODONE CR · OXY.IR · OXYCODONE · +16 more | 68 | 28 | Yes |
| Codein, Combinations With Psycholeptics | APO-BUTALBITAL-ACETYLSALICYLIC ACID-CAFFEINE-CODEINE-C 1/2 · APO-BUTALBITAL-ACETYLSALICYLIC ACID-CAFFEINE-CODEINE-C 1/4 · FIORINAL-C 1/2 · FIORINAL-C 1/4 · +13 more | 17 | 6 | Yes |
| Oxycodone And Naloxone | TARGIN | 4 | 4 | Yes |
| Codeine, Combinations Excl. Psycholeptics | AXACET-C1/8 · AXISAL-C1/8 · METHOXACET-C 1/8 · METHOXISAL-C 1/2 · +21 more | 25 | 1 | Yes |
| Natural Opium Alkaloids | NUMORPHAN INJECTION 1.5MG/ML · NUMORPHAN SUPPOSITORY 5MG · OPANA ER | 6 | 0 | Not in Canada |
| Opium | OPIUM TEINTURE | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC N02A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| N02AX | Tapentadol · Tramadol | 41 | 30 |
| N02AJ | Codeine And Acetylsalicylic Acid · Codeine And Paracetamol · Hydrocodone And Ibuprofen · Oxycodone And Acetylsalicylic Acid · Oxycodone And Paracetamol · +1 more | 137 | 21 |
| N02AB | Fentanyl · Pethidine | 105 | 17 |
| N02AE | Buprenorphine | 15 | 4 |
| N02AF | Butorphanol · Nalbufine | 5 | 2 |
| N02AG | Opioids In Comb With Antispasmodics | 3 | 0 |
| N02AD | Pentazocine | 3 | 0 |
| N02AC | Dextropropoxyphene · Dextropropoxyphene, Comb Excl Psycholept | 7 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is HYDROMORPHONE called?
The same molecule, Hydromorphone, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Dilaudid | Latin | Australia |
| Hikma | Latin | Australia |
| Dilaudid-HP | Latin | Australia |
| HYDROMORPHONE JUNO | Latin | Australia |
| HYDROMORPHONE JUNO-HP | Latin | Australia |
| Hydromorphone-hameln | Latin | Australia |
| Hydromorphone-hameln-HP | Latin | Australia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.